Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) regimen is frequently used to treat early and locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) in neoadjuvant setting. However, large-scaled real-world evidence did not exist. Materials and methods: We retrospectively reviewed medical records of patients with early or locally advanced HER2-positive BC who underwent neoadjuvant TCHP followed by curative surgery at Samsung Medical Center between January 2016 and August 2020. Results: Of 447 patients, 316 (70.7%) received breast-conserving surgery and 131 (29.3%) received total mastectomy. In terms of neoadjuvant chemotherapy response, pathologic complete response (pCR) and residual cancer burden (RCB) score were analyzed. The rate of pCR was 64% a class of RCB 0 was observed in 65% of cases, RCB class I in 12%, RCB class II in 14%, and RCB class III in 2%. The 3-year event-free survival rate was 90.6%, BC with pCR occurred in 92.8%, and BC with non-pCR in 86.3% (p=0.016). In terms of distant metastasis, the 3-year distant recurrence-free survival rate was 93.5%; BC with pCR occurred in 95.9% and BC with non-pCR in 89.2% (p=0.013). Mucositis (85.2%), pain (83.2%), and diarrhea (70.5%) were the most common non-hematologic adverse events. In terms of hematologic adverse events, anemia (89.9%) was the most commonly observed adverse events followed by thrombocytopenia (29.8%). Conclusion: Neoadjuvant TCHP therapy had a pCR rate of 64% and a 3-year event-free survival of 90% in real world experience. In terms of toxicity profile, anemia was frequently observed and adequate management including occasional transfusion was required.
Abstract
Purpose: Docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) regimen is frequently used to treat early and locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) in neoadjuvant setting. However, large-scaled real-world evidence did not exist. Materials and methods: We retrospectively reviewed medical records of patients with early or locally advanced HER2-positive BC who underwent neoadjuvant TCHP followed by curative surgery at Samsung Medical Center between January 2016 and August 2020. Results: Of 447 patients, 316 (70.7%) received breast-conserving surgery and 131 (29.3%) received total mastectomy. In terms of neoadjuvant chemotherapy response, pathologic complete response (pCR) and residual cancer burden (RCB) score were analyzed. The rate of pCR was 64% a class of RCB 0 was observed in 65% of cases, RCB class I in 12%, RCB class II in 14%, and RCB class III in 2%. The 3-year event-free survival rate was 90.6%, BC with pCR occurred in 92.8%, and BC with non-pCR in 86.3% (p=0.016). In terms of distant metastasis, the 3-year distant recurrence-free survival rate was 93.5%; BC with pCR occurred in 95.9% and BC with non-pCR in 89.2% (p=0.013). Mucositis (85.2%), pain (83.2%), and diarrhea (70.5%) were the most common non-hematologic adverse events. In terms of hematologic adverse events, anemia (89.9%) was the most commonly observed adverse events followed by thrombocytopenia (29.8%). Conclusion: Neoadjuvant TCHP therapy had a pCR rate of 64% and a 3-year event-free survival of 90% in real world experience. In terms of toxicity profile, anemia was frequently observed and adequate management including occasional transfusion was required.
참고문헌 (18)
- Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", N Engl J Med, 344, pp.783~792 (2001)
- Slamon D, "Adjuvant trastuzumab in HER2-positive breast cancer", N Engl J Med, 365, pp.1273~1283 (2011)
- Gianni L, "Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer(NOAH) : follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort", Lancet Oncol, 15, pp.640~647 (2014)
- Baselga J, "Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer", N Engl J Med, 366, pp.109~119 (2012)
- Swain SM, "Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer", N Engl J Med, 372, pp.724~734 (2015)
- von Minckwitz G, "Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer", N Engl J Med, 377, pp.122~131 (2017)
- Gianni L, "Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer(NeoSphere) : a randomised multicentre, open-label, phase 2 trial", Lancet Oncol, 13, pp.25~32 (2012)
- Swain SM, "Pertuzumab, trastuzumab, and standard anthracycline-and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer(BERENICE) : a phase II, open-label, multicenter, multinational cardiac safety study", Ann Oncol, 29, pp.646~653 (2018)
- Gianni L, "5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer(NeoSphere) : a multicentre, open-label, phase 2 randomised trial", Lancet Oncol, 17, pp.791~800 (2016)
- Cardoso F, "Early breast cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger", Ann Oncol, 30, pp.1194~1220 (2019)
- Denduluri N, "Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer : ASCO guideline update", J Clin Oncol, 39, pp.685~693 (2021)
- Schneeweiss A, "Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer : a randomized phase II cardiac safety study(TRYPHAENA)", Ann Oncol, 24, pp.2278~2284 (2013)
- Schneeweiss A, "Long-term efficacy analysis of the ran-domised, phase II TRYPHAENA cardiac safety study : evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer", Eur J Cancer, 89, pp.27~35 (2018)
- von Minckwitz G, "Trastuzumab emtansine for residual invasive HER2-positive breast cancer", N Engl J Med, 380, pp.617~628 (2019)
- Symmans WF, "Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy", J Clin Oncol, 25, pp.4414~4422 (2007)
- Cortazar P, "Pathological complete response in neoadjuvant treatment of breast cancer", Ann Surg Oncol, 22, pp.1441~1446 (2015)
- Miles D, "Effect of docetaxel duration on clinical outcomes : exploratory analysis of CLEOPATRA, a phase III randomized controlled trial", Ann Oncol, 28, pp.2761~2767 (2017)
- Swain SM, "Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer : results from the phase III trial CLEOPATRA", Oncologist, 19, pp.693~701 (2014)